Table 1.
The baseline characteristics of ICC patients in training and validation sets
| Variable | Whole set (n = 101) | Training set (n = 77) | Validation set (n = 24) | p |
|---|---|---|---|---|
| Sex, male, n (%) | 55 (54.5) | 40 (51.9) | 15 (62.5) | 0.365 |
| Age, mean ± SD, years | 58.2 ± 10.8 | 58.5 ± 10.9 | 56.9 ± 10.7 | 0.458 |
| Hypertension, n (%) | 0.995 | |||
| Yes | 21 (20.8) | 16 (20.8) | 5 (20.8) | |
| No | 80 (79.2) | 61 (79.2) | 19 (79.2) | |
| Diabetes, n (%) | 0.932 | |||
| Yes | 8 (7.9) | 6 (7.8) | 2 (8.3) | |
| No | 93 (92.1) | 71 (92.2) | 22 (91.7) | |
| Hepatitis B, n (%) | 27 (26.7) | 21 (27.3) | 6 (25.0) | 0.826 |
| Liver cirrhosis, n (%) | 0.074 | |||
| Present | 13 (12.9) | 7 (9.1) | 6 (25.0) | |
| Absent | 88 (87.1) | 70 (90.9) | 18 (75.0) | |
| Hypersplenism, n (%) | 0.421 | |||
| Yes | 2 (2.0) | 1 (1.3) | 1 (4.2) | |
| No | 99 (98.0) | 76 (98.7) | 23 (95.8) | |
| ALT, mean ± SD, IU/L | 36.0 ± 38.6 | 33.8 ± 37.3 | 43.3 ± 42.4 | 0.131 |
| AST, mean ± SD, IU/L | 38.7 ± 34.9 | 35.8 ± 34.4 | 48.6 ± 35.7 | 0.024 |
| ALB, mean ± SD, g/L | 41.6 ± 4.1 | 41.8 ± 3.7 | 41.2 ± 5.1 | 0.941 |
| TBIL, mean ± SD, μmol/L | 15.2 ± 16.5 | 13.6 ± 8.2 | 20.6 ± 30.7 | 0.095 |
| PT, mean ± SD, s | 11.7 ± 1.6 | 11.5 ± 1.0 | 12.3 ± 2.8 | 0.357 |
| INR, mean ± SD | 1.0 ± 0.1 | 1.0 ± 0.1 | 1.1 ± 0.2 | 0.362 |
| AFP, mean ± SD, ng/mL | 40.0 ± 189.7 | 29.1 ± 150.4 | 74.6 ± 283.6 | 0.624 |
| CA 125, mean ± SD, U/mL | 50.0 ± 82.8 | 47.3 ± 67.5 | 58.0 ± 120.9 | 0.106 |
| CA 19-9, mean ± SD, U/mL | 322.6 ± 393.5 | 321.2 ± 404.3 | 327.5 ± 365.4 | 0.515 |
| CEA, mean ± SD, ng/mL | 18.2 ± 71.1 | 13.0 ± 36.1 | 36.9 ± 137.6 | 0.333 |
| Tumor size, n (%) | 0.455 | |||
| ≤ 5 cm | 27 (26.7) | 22 (28.6) | 5 (20.8) | |
| > 5 cm | 74 (73.3) | 55 (71.4) | 19 (79.2) | |
| Differentiation | 0.084 | |||
| Well | 1 (1.0) | 0 | 1 (4.2) | |
| Moderate | 36 (35.6) | 31 (40.3) | 5 (20.8) | |
| Poor | 57 (56.4) | 40 (51.9) | 17 (70.8) | |
| Unclear | 7 (6.9) | 6 (7.8) | 1 (4.2) | |
| OS, mean ± SD, m | 19.9 ± 17.6 | 21.3 ± 18.6 | 15.6 ± 13.3 | 0.300 |
Abbreviations: ICC Intrahepatic cholangiocarcinoma, SD Standard deviation, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ALB Albumin, TBIL Total bilirubin, PT Prothrombin time, INR International normalized ratio, AFP Alpha fetoprotein, CA Carbohydrate antigen, CEA Carcinoembryonic antigen, OS Overall survival